An interventional study of Infliximab and Instillation of fibrin glue in Crohn's Disease, sponsored by Sheba Medical Center. Terminated at 4 sites in Israel. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2009-04-24.
Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment
This study is aimed to assess the hypothesis that instillation of fibrin glue with the induction of local conditions using Infliximab, may be useful in the treatment of perianal Crohn's disease.
Patients with perianal fistulae of Crohn's disease will be prospectively enrolled and receive 3 doses of Infliximab. If reduction of fistula associated discharge of at least 50% will be recorded, commercially available fibrin glue will be instilled into the fistula tract using standard surgical techniques. The patients will be followed for 6 months for fistula healing and complications.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
Browse Crohn Disease studies →Sheba Medical Center is the lead sponsor of 660 studies on the registry; 63 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Fistula healing
Quality of life
Complications
This study is terminated, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sheba Medical Center